IP Library Granted Patent US 8,895,606
Granted Patent B2
US 8,895,606 · App. 13/818,647 · Granted Nov 25, 2014

Proline sulfonamide derivatives as orexin receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,606
App. No.
13/818,647
Granted
Nov 25, 2014
Kind
B2
Abstract

The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R 1 and R 2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.

Claims (9)

1. A pharmaceutical composition comprising the compound (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide.

2. A pharmaceutical composition comprising the compound (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition according to claim 2 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.

4. A method for treatment of sleep disorders comprising administering to a subject in need thereof a pharmaceutical composition according to claim 1 .

5. A method according to claim 4 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.

6. A method for treatment of sleep disorders comprising administering to a subject in need thereof a pharmaceutical composition according to claim 2 .

7. A method according to claim 4 , wherein the sleep disorder is primary insomnia.

8. A method according to claim 5 , wherein the sleep disorder is primary insomnia.

9. A method according to claim 6 , wherein the sleep disorder is primary insomnia.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042464 FRAME: 0407. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 043017/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 042464/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2014
From: BOSS, CHRISTOPH; BROTSCHI, CHRISTINE; GATFIELD, JOHN; GUDE, MARKUS; HEIDMANN, BIBIA; SIFFERLEN, THIERRY; WILLIAMS, JODI T.
To: ACTELION PHARMACEUTICALS LTD.
Reel/Frame 033405/0058 →